Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company Alexion Pharmaceuticals (NASDAQ:ALXN) climbed 10% today after its quarterly results and outlook topped Wall Street expectations.
So what: The stock was hammered in October on concerns over slowing growth, but a wide first-quarter beat -- adjusted EPS of $0.65 versus the consensus of $0.61 -- coupled with upbeat guidance, is quickly easing those concerns. In fact, sales of its key blood disorder drug Soliris spiked 38% to $338.9 million during the quarter, reigniting investor optimism over its mega blockbuster potential going forward.
Now what: Management now sees full-year adjusted EPS of $2.87-$2.97 on $1.51 billion-$1.52 billion, nicely above its prior view of $2.82-$2.92, and $1.49 billion-$1.51 billion. "The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in the US," said the company in a statement. More important, with the stock still off about 20% from its 52-week highs, biotech-savvy investors might have some room left to gain from that growth.
Interested in more info Alexion? Add it to your watchlist.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.